Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines

This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.IC: NIAIDNIH Ref. No.: E-195-2014/0Advantages: Broad/universal protection against influenza virusesDoes not require reformulating vaccine each year as is currently necessary with vaccines available on the marketCan potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza virusesApplications: VaccinesProvider Technology ID: 3081Updated On: Nov 22, 2016Date Published: Tuesday, November 22, 2016Provider Classifications: Publications: Patent Application: PCT/US2015/02984362/014,821Patent Authority: PCTUS2016-12-01 00:00:002016-12-01 00:00:00Licensing Contacts: LPM Address:   --United StatesLead Inventor: Inventor IC: NIAIDInventor Lab URL: http://irp.nih.gov/pi/jeffery-taubenbergerLPM FIrst Name: JenishLPM Last Name: PatelLP...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research